PMN

MKT CAP:$15M

ProMIS Neurosciences, Inc.

Market Cap

$15M

Healthcare·Biotechnology·🇨🇦 Canada·NASDAQ

Healthcare·Biotechnology·🇨🇦·NASDAQ

Stock Price

$10.88+$3.74 (+52.38%)

Apr 23, 2026

Company Details

ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Ca...

CEO

Neil K. Warma

IPO Date

Jan 10, 2007

Website

www.promisneurosciences.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$29M

EPS (Diluted)

-$21.02

Free Cash Flow

-$27M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q4 2025

May 11, 2026

PENDING

FY 2025

Mar 25, 2026

$0EPS -$22.61

Q3 2025

Nov 12, 2025

$0EPS -$8.27

Q2 2025

Aug 13, 2025

$0EPS -$7.25

Q1 2025

May 12, 2025

$0EPS -$5.25

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 21	$0	-$8.8K	-$306.2K
Q2 21	$0	-$9.1K	-$986.5K
Q2 22	$0	$0	-$5M
Q3 22	$0	$0	-$6M
Q4 22	$0	-$1.6K	-$9M
Q1 23	$0	$0	-$5M
Q2 23	$0	$0	-$3M
Q3 23	$0	$0	-$3M
Q4 23	$0	-$18.0K	-$4M
Q1 24	$0	$0	-$4M
Q2 24	$0	$0	-$3M
Q3 24	$0	$0	-$4M
Q4 24	$0	$0	-$6M
Q1 25	$0	$0	-$7M
Q2 25	$0	$0	-$10M
Q3 25	$0	$0	-$12M

Valuation

Quarter	P/S	P/E
Q1 21	38575.8x	—
Q2 21	—	—
Q2 22	—	—
Q3 22	—	—
Q4 22	—	—
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	—	—
Q1 24	—	—
Q2 24	—	—
Q3 24	—	—
Q4 24	—	11.3x
Q1 25	—	—
Q2 25	—	—
Q3 25	—	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 21	-$568.2K	-$568.2K
Q2 21	-$1M	$0
Q2 22	-$4M	-$4M
Q3 22	-$5M	-$5M
Q4 22	-$5M	-$5M
Q1 23	-$3M	-$3M
Q2 23	-$2M	-$2M
Q3 23	-$2M	-$2M
Q4 23	-$4M	-$4M
Q1 24	-$10M	-$10M
Q2 24	-$2M	-$2M
Q3 24	-$7M	-$7M
Q4 24	-$8M	-$8M
Q1 25	-$5M	-$5M
Q2 25	-$4M	-$4M
Q3 25	-$10M	-$10M

Capital Expenditures

Quarter	CapEx
Q1 21	$0
Q2 21	$1M
Q2 22	$0
Q3 22	$24
Q4 22	$2.0K
Q1 23	$0
Q2 23	$0
Q3 23	$0
Q4 23	$1
Q1 24	$0
Q2 24	$0
Q3 24	$0
Q4 24	$3
Q1 25	$3
Q2 25	$0
Q3 25	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 21	—	+123.8%
Q2 21	-100.0%	+181.9%
Q2 22	—	+525.6%
Q3 22	—	-22.1%
Q4 22	—	+2683.5%
Q1 23	—	+403.9%
Q2 23	—	-40.4%
Q3 23	—	-58.4%
Q4 23	—	-54.5%
Q1 24	—	-26.0%
Q2 24	—	-6.4%
Q3 24	—	+76.2%
Q4 24	—	+54.9%
Q1 25	—	+102.9%
Q2 25	—	+275.3%
Q3 25	—	+165.0%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 21	-$39.5K	—
Q2 21	$0	—
Q2 22	$115.4K	—
Q3 22	$108.6K	—
Q4 22	$138.8K	—
Q1 23	$132.5K	—
Q2 23	$134.2K	—
Q3 23	$0	—
Q4 23	$0	—
Q1 24	$63.6K	—
Q2 24	$18.0K	—
Q3 24	$121.0K	—
Q4 24	$623.2K	—
Q1 25	$245.3K	—
Q2 25	$212.0K	—
Q3 25	$0	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 21	$103.1K	—	$194.3K
Q2 21	$624.9K	—	$352.5K
Q2 22	$3M	$2M	—
Q3 22	$5M	$1M	—
Q4 22	$6M	—	$2M
Q1 23	$4M	$1M	—
Q2 23	$1M	$2M	—
Q3 23	$1M	$1M	—
Q4 23	$2M	—	$2M
Q1 24	$2M	$2M	—
Q2 24	$2M	$1M	—
Q3 24	$3M	$2M	—
Q4 24	$4M	—	$2M
Q1 25	$5M	$2M	—
Q2 25	$9M	$1M	—
Q3 25	$10M	$2M	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 21	$16M	$37.0K	$16M
Q1 22	$17M	$61.8K	$17M
Q2 22	$11M	$59.6K	$12M
Q3 22	$5M	$59.7K	$5M
Q4 22	$8M	$59.5K	$8M
Q1 23	$3M	$31.1K	$3M
Q2 23	$2M	$59.7K	$2M
Q3 23	$23M	$69.9K	$23M
Q4 23	$13M	$32.4K	$13M
Q1 24	$2M	$32.4K	$3M
Q2 24	$992.5K	$32.4K	$1M
Q3 24	$22M	$32.4K	$22M
Q4 24	$13M	$33.1K	$13M
Q1 25	$8M	$33.1K	$8M
Q2 25	$5M	$33.1K	$5M
Q3 25	$15M	$33.0K	$15M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 21	196K	+1.5%	+5.7%
Q2 21	204K	+4.0%	+7.5%
Q2 22	288K	+41.1%	+49.0%
Q3 22	288K	0.0%	+49.0%
Q4 22	337K	+17.1%	+71.8%
Q1 23	343K	+1.8%	+68.2%
Q2 23	343K	0.0%	+19.2%
Q3 23	495K	+44.2%	+71.9%
Q4 23	783K	+58.3%	+132.5%
Q1 24	781K	-0.3%	+127.7%
Q2 24	791K	+1.2%	+130.5%
Q3 24	1M	+52.1%	+143.0%
Q4 24	1M	+15.8%	+77.8%
Q1 25	1M	+0.1%	+78.4%
Q2 25	1M	+0.0%	+76.3%
Q3 25	1M	0.0%	+15.9%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 21	—	—
Q2 21	—	—
Q2 22	—	—
Q3 22	—	—
Q4 22	$0	6
Q1 23	$0	6
Q2 23	$0	6
Q3 23	$0	6
Q4 23	$0	6
Q1 24	$0	6
Q2 24	$0	6
Q3 24	$0	6
Q4 24	$0	7
Q1 25	$0	7
Q2 25	$0	7
Q3 25	$0	7

Revenue / Employee